Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ABBV-744 |
Trade Name | |
Synonyms | ABBV744|ABBV 744 |
Drug Descriptions |
ABBV-744 is a bromodomain II selective BET inhibitor, which potentially inhibits tumor cell proliferation and decreases tumor growth (Cancer Res 2018;78(13 Suppl):Abstract nr DDT01-05, PMID: 31969702, PMID: 32324999). |
DrugClasses | BET Inhibitor (Pan) 32 |
CAS Registry Number | 2138861-99-9 |
NCIT ID | C148415 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ABBV-744 | ABBV-744 | 0 | 2 |
ABBV-744 + Navitoclax | ABBV-744 Navitoclax | 0 | 1 |
ABBV-744 + Ruxolitinib | ABBV-744 Ruxolitinib | 0 | 1 |